BLSM - BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
Story updates
11:01:19 AM UTC
SquawkNews
Strengthened balance sheet with successful completion of upsized $168.3 million initial public offeringAnnounced FDA Fast Track designation for BH-30643 for the treatment of advancedEGFR C797S-positive NSCLCSAN DIEGO, Sept. 18, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. NASDAQ:BLSM, a…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.